KalVista Pharmaceuticals, Inc. (KALV) Stock
KALV has an Alpha Score of 8 out of 100 (poor), computed on Nov 7, 2026 from 1 of 4 sub-scores. 1 member of Congress disclosed 1 trade in KALV since 2022: 1 purchase and 0 sales, most recently Christopher L. Jacobs (purchase, Dec 12, 2022).
What is KALV's Alpha Score?
How it works →Alpha Score of 8 reflects poor overall profile with poor quality. Based on 1 of 4 signals – score is capped at 50 until remaining data ingests.
Computed from 1 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 7, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded KalVista Pharmaceuticals, Inc. (KALV)?
Most recent: Christopher L. Jacobs (purchase, Dec 12, 2022); records start Dec 12, 2022.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Chris Jacobs R-NY · House | 2022-12-12 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 9, 2026.
See all KALV political trades →What are KALV's key statistics?
Key statistics as of Oct 30, 2026
How does KALV's valuation compare with the Healthcare sector?
| Metric | KALV | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -91.58% | 3.60% | 175 |
| Return on equity | -237.53% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
KALV price chart
Powered by TradingViewWhat does KalVista Pharmaceuticals, Inc. do?
KalVista Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet medical needs, particularly hereditary angioedema (HAE). Its lead product, EKTERLY (sebetralstat), is an FDA-approved oral on-demand plasma kallikrein inhibitor designed to treat acute HAE attacks, offering a convenient alternative to injectable therapies by enabling rapid symptom relief when taken at the onset of an attack. The company is also advancing other oral formulations, including an orally disintegrating tablet version called KONFIDENT-KID tailored for pediatric patients, and a preclinical Factor XIIa inhibitor, both targeting HAE to expand treatment options across age groups. KalVista Pharmaceuticals Inc. operates in the rare disease space, emphasizing patient-centric innovations that improve treatment adherence and satisfaction through non-invasive delivery. With regulatory approvals in multiple markets and partnerships for international expansion, it plays a key role in transforming on-demand HAE management by prioritizing oral therapies that address limitations of existing standards.